Immunocore (NASDAQ:IMCR) Downgraded by Zacks Research to “Hold”

Immunocore (NASDAQ:IMCR) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other research analysts also recently commented on the company. UBS Group set a $55.00 target price on Immunocore and gave the stock a “buy” rating in a report on Wednesday, January 7th. Mizuho set a $38.00 price target on shares of Immunocore in a research report on Thursday, February 19th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, February 4th. Morgan Stanley upped their price target on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th. Finally, Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.30.

Immunocore Stock Performance

NASDAQ:IMCR opened at $32.04 on Wednesday. The firm has a market capitalization of $1.62 billion, a PE ratio of -45.77 and a beta of 0.78. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. Immunocore has a 12-month low of $23.15 and a 12-month high of $40.71. The firm has a 50-day moving average price of $33.55 and a 200 day moving average price of $34.32.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.32). Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.16%. The company had revenue of $104.48 million for the quarter, compared to analyst estimates of $145.48 million. During the same period in the previous year, the firm posted ($0.47) earnings per share. The firm’s revenue for the quarter was up 24.3% compared to the same quarter last year. Research analysts anticipate that Immunocore will post -0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunocore

In other Immunocore news, insider David M. Berman sold 5,965 shares of Immunocore stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $192,967.75. Following the transaction, the insider owned 5,859 shares of the company’s stock, valued at approximately $189,538.65. The trade was a 50.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Bahija Jallal sold 11,474 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total transaction of $371,183.90. Following the sale, the chief executive officer directly owned 12,343 shares of the company’s stock, valued at $399,296.05. This represents a 48.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 19,137 shares of company stock valued at $619,082. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunocore

A number of institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new position in Immunocore during the second quarter worth $1,621,000. Acadian Asset Management LLC lifted its position in Immunocore by 392.3% during the 2nd quarter. Acadian Asset Management LLC now owns 90,798 shares of the company’s stock worth $2,843,000 after buying an additional 72,355 shares in the last quarter. Eschler Asset Management LLP acquired a new position in shares of Immunocore during the 2nd quarter worth about $1,255,000. Frazier Life Sciences Management L.P. grew its holdings in shares of Immunocore by 27.8% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 384,782 shares of the company’s stock valued at $12,074,000 after acquiring an additional 83,612 shares in the last quarter. Finally, Fiera Capital Corp increased its position in shares of Immunocore by 1.0% in the second quarter. Fiera Capital Corp now owns 813,074 shares of the company’s stock valued at $25,514,000 after acquiring an additional 7,924 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Analyst upgrade and higher price target — Needham raised its price target from $71 to $75 and kept a Buy rating, implying substantial upside vs. the current share price. Benzinga
• Positive Sentiment: Strong product sales and cash runway — KIMMTRAK net sales were $104.5M in Q4 and $400M for FY2025; company ended the year with ~$864.2M in cash, cash equivalents and marketable securities, supporting R&D and runway. Press Release
• Positive Sentiment: Near-term clinical catalysts — Management expects TEBE‑AM enrollment completion 1H2026 with topline as early as 2H2026; multiple PRAME franchise and HIV Phase 1/2 readouts also slated in 2H2026 — potential value-inflecting events. Pipeline Update
• Neutral Sentiment: Full earnings materials available — Management hosted a conference call and released slide deck and transcripts; these provide color on commercialization, trial timelines and cost structure. Earnings Transcript
• Negative Sentiment: Quarterly misses and guidance tone — Q4 EPS of ($0.60) missed consensus (~($0.28)) and revenue of $104.48M materially missed the ~$145M estimate; company cautioned that revenue growth will moderate in 2026, which reduces near-term upside. Earnings Release / Slide Deck

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.